Diagnostic framework of biomarkers for Parkinson′s disease
10.3760/cma.j.cn113694-20241212-00798
- VernacularTitle:帕金森病生物学标志物诊断框架
- Author:
Xiuyuan LI
1
;
Yilin TANG
1
;
Jian WANG
1
Author Information
1. 复旦大学附属华山医院神经内科，上海 200040
- Publication Type:Journal Article
- Keywords:
Parkinson disease;
Biomarkers;
Diagnostic framework;
α-Synuclein;
Neurodegeneration
- From:
Chinese Journal of Neurology
2025;58(9):913-919
- CountryChina
- Language:Chinese
-
Abstract:
Parkinson′s disease (PD) is a neurodegenerative disorder primarily characterized by motor dysfunctions, yet it currently lacks a "gold standard" for clinical diagnosis and staging. This poses significant challenges for early diagnosis with accuracy and the objective assessment of disease severity. In recent years, the study of biological markers in PD has gained increasing attention. At the International Congress of PD and Movement Disorders in 2023, 2 biomarker-based diagnostic frameworks were proposed: SynNeurGe and NSD-ISS. The SynNeurGe framework emphasizes classification by integrating α-synuclein (α-syn, S), neurodegeneration (N) and genetic variants (G), while the NSD-ISS framework focuses on redefinition and staging, centering on neuronal α-syn pathology. Despite their different target populations and focuses, both frameworks reflect a clear trend toward biomarker-driven and objective approaches in PD diagnosis. Current research priorities include validating the reproducibility and improving the accessibility of biomarker detection methods and developing in vivo neuroimaging techniques for α-syn aggregation, aiming to facilitate disease-modifying therapy for PD.
